Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Maarten J, Deenen"'
Autor:
Drs. Merel L.J.M. Janssen, Dr. Carolien M.J. van der Linden, Dr. Maarten J. Deenen, Dr. Petra E. Spies, Drs. Anne Jacobs
Publikováno v:
Diabetes Epidemiology and Management, Vol 12, Iss , Pp 100157- (2023)
Aims: GLP-1-analogues, DPP4-inhibitors, and SGLT2-inhibitors have become available to treat type 2 diabetes. The extent to which these glucose regulating agents (GRA) are prescribed to older patients is unknown. Methods: We performed a retrospective
Externí odkaz:
https://doaj.org/article/34ea688a969544ffb8ce70846ee7ab6f
Autor:
Catharina H. M. Kerskes, Carien J. M. E. van den Eijnde, Albert-Jan L. H. J. Aarnoudse, René J. E. Grouls, Birgit A. L. M. Deiman, Maarten J. Deenen
Publikováno v:
Pharmacy, Vol 11, Iss 2, p 69 (2023)
Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity. This study
Externí odkaz:
https://doaj.org/article/5f0d293880d54b47baaf7acae7165980
Autor:
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 940-950 (2019)
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐
Externí odkaz:
https://doaj.org/article/8300a5fe4be74766ad22f7c77488aab7
Autor:
Joost Nederend, Robin J. Lurvink, Paulien Rauwerdink, Koen P. Rovers, Emma C.E. Wassenaar, Maarten J. Deenen, Clément J.R. Huysentruyt
Publikováno v:
BMJ Open, Vol 11, Iss 3 (2021)
Introduction Despite its increasing use, first-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX), hereinafter referred to as first-line bidirectional therapy,
Externí odkaz:
https://doaj.org/article/8f8b3968e29140ac86d4dc0c04cb99b2
Autor:
Emma C. Hulshof, Lifani Lim, Ignace H. J. T. de Hingh, Hans Gelderblom, Henk-Jan Guchelaar, Maarten J. Deenen
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundThe introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase i
Externí odkaz:
https://doaj.org/article/a9d401b97a414b9c8aa448d580ac8221
Autor:
Maarten J Deenen, Koen P Rovers, Robin J Lurvink, Emma CE Wassenaar, Thomas JM Kootstra, Harm J Scholten, Rudaba Tajzai, Joost Nederend, Max J Lahaye, Clément JR Huysentruyt, Iris van ’t Erve, Remond JA Fijneman, Alexander Constantinides, Onno Kranenburg, Maartje Los, Anna MJ Thijs, Geert-Jan M Creemers, Jacobus WA Burger, Marinus J Wiezer, Djamila Boerma, Simon W Nienhuijs, Ignace HJT de Hingh
Publikováno v:
BMJ Open, Vol 9, Iss 7 (2019)
Introduction Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several c
Externí odkaz:
https://doaj.org/article/c7c7a260fb6341a386a5b94518c0ddbf
Autor:
Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking. Therefore, we analyzed the toxicity and effectiveness of fixed-dose c
Externí odkaz:
https://doaj.org/article/83660daccf0142229ea5b2375699afac
Autor:
Annemieke Cats, Jan H.M. Schellens, Cornelis J.A. Punt, Jos H. Beijnen, Paul H.M. Smits, Henk-Jan Guchelaar, Andrew Vincent, Anthonius de Boer, Valerie D. Doodeman, Artur M Burylo, Jolien Tol, Maarten J. Deenen
Supplementary Figure S1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bca2b87f674d91b3e5d17cedc2bf202
https://doi.org/10.1158/1078-0432.22440949
https://doi.org/10.1158/1078-0432.22440949
Autor:
Annemieke Cats, Jan H.M. Schellens, Cornelis J.A. Punt, Jos H. Beijnen, Paul H.M. Smits, Henk-Jan Guchelaar, Andrew Vincent, Anthonius de Boer, Valerie D. Doodeman, Artur M Burylo, Jolien Tol, Maarten J. Deenen
Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine.Experimental Design: Germline DNA was available from 568 previously untreated patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751a6d131b7991bca7a48c1bb0800849
https://doi.org/10.1158/1078-0432.c.6518164.v1
https://doi.org/10.1158/1078-0432.c.6518164.v1
Autor:
Emma C. Hulshof, Mirjam de With, Geert-Jan Creemers, Henk-Jan Guchelaar, Ron HJ. Mathijssen, Hans Gelderblom, Maarten J. Deenen
Publikováno v:
European Journal of Cancer. 172:231-233
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a665fdfa1cdfb6b21a63c6b1d34ab781
https://doi.org/10.1016/j.ejca.2022.05.045
https://doi.org/10.1016/j.ejca.2022.05.045